Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Ovarian suppression with tamoxifen reduced recurrence for some women with premenopausal breast cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 12.12.14
Views: 5453
Rating:

Dr Prudence Francis - Peter MacCallum Cancer Centre, Melbourne, Australia

Dr Francis talks to ecancer at the 2014 San Antonio Breast Cancer Symposium (SABCS).

Among premenopausal women with early-stage, hormone receptor-positive breast cancer, adding ovarian suppression to tamoxifen reduced breast cancer recurrence for those who had previously received chemotherapy and remained premenopausal, according to data from the randomised, phase III suppression of ovarian function trial (SOFT).

Watch the press conference or read the news story for more.

Related videos

follow us

Neutropenia


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation